Short-Term Outcomes of Refractory Diabetic Macular Edema Switch From Ranibizumab to Dexamethasone Implant and the Influential Factors: A Retrospective Real World Experience

Ning-Yi Hsia[1], Chun-Ju Lin[1,2,3]*, Huan-Sheng Chen[4], Cheng-Hsien Chang[1,2,3], Henry Bair[1,5], Chun-Ting Lai[1], Jane-Ming Lin[1,3], Wen-Lu Chen[1,3], Peng-Tai Tien[1,6], Wen-Chuan Wu[1] and Yi-Yu Tsai[1,2,3]

[1] Department of Ophthalmology, Eye Center, China Medical University Hospital, Taichung, Taiwan, [2] School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan, [3] Department of Optometry, Asia University, Taichung, Taiwan, [4] An-Shin Dialysis Center, NephroCare Ltd., Fresenius Medical Care, Taichung, Taiwan, [5] School of Medicine, Stanford University, Stanford, CA, United States, [6] Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan

Introduction: To evaluate the effectiveness and safety of intravitreal dexamethasone (DEX) implants in refractory diabetic macular edema (DME) treated by intravitreal ranibizumab.

Materials and Methods: We retrospectively analyzed DME patients who received DEX implant treatment after being refractory to at least 3 monthly intravitreal ranibizumab injections. The main outcomes were best-corrected visual acuity (BCVA), central retinal thickness (CRT), and intraocular pressure (IOP).

Results: Twenty-nine eyes of 26 patients who had previously received an average of 8.1 ± 4.4 ranibizumab injections were included. Patients received between one and three DEX implants during 12.4 ± 7.4 months of follow-up. The mean final CRT significantly decreased from $384.4 \pm 114.4\,\mu m$ at baseline to $323.9 \pm 77.7\,\mu m$ ($p = 0.0249$). The mean final BCVA was 51.4 ± 21.3 letters, which was not significant compared to baseline (44.9 ± 30.2 letters, $p = 0.1149$). Mean IOP did not increase significantly. All patients tolerated the treatment well without serious adverse events. Higher baseline CRT and worse BCVA correlated with better therapeutic responses.

Conclusion: Switching to DEX implant is feasible and safe for treating patients of DME refractory to intravitreal ranibizumab in real world. Further larger-scale or multicenter studies would be conducted to explore different DEX treatment strategies for DME, such as first-line or early switch therapy, for better BCVA improvement.

Keywords: diabetic macular edema, intravitreal dexamethasone implant, intravitreal ranibizumab, ozurdex, refractory diabetic macular edema

INTRODUCTION

Diabetes mellitus is one of the most important global health issues of the twenty-first century. At present, there are 425 million patients with diabetes worldwide, and this number is projected to reach 629 million by 2045 (1). Diabetic retinopathy, a microvascular complication of diabetes, has an estimated prevalence of 34.6% among patients with diabetes. Diabetic macular edema (DME), a manifestation of diabetic retinopathy, develops in ∼6.8% of patients with diabetes and is a major cause of visual loss in this population (2).

Hyperglycemia in diabetes increases oxidative stress, inflammation, and vascular dysfunction. Oxidative stress and inflammation induce the upregulation of growth factors, such as vascular endothelial growth factor (VEGF) and cytokines, which contribute to the breakdown of the blood-retinal barrier (BRB) by disrupting the integrity of retinal vascular endothelial cell tight junctions and increasing vascular permeability (3). The ensuing fluid accumulation, in addition to the persistent presence of inflammatory factors, causes dysfunction of the inner nuclear layer and subsequent development of DME (4).

VEGF antagonists are frequently used as intravitreal treatments for DME, as several studies reveal that patients with DME had favorable visual and anatomic responses to ranibizumab (5, 6). However, there are still patients who, after a favorable initial response to anti-VEGF agents, show decreased responses over time and became resistant to further intravitreal injections. This may be a result of inflammatory mediators other than VEGF contributing to the persistence of DME (7). Increasing dosages of intravitreal injections are needed to control the disease. However, this carries an increased risk of complications and poor compliance (8).

Corticosteroids have been demonstrated to inhibit the expression of VEGF and other inflammatory factors, thus reinforcing the BRB. The biodegradable intravitreal dexamethasone (DEX) implant provides sustained release of the anti-inflammatory corticosteroid dexamethasone into the vitreous. DEX implants have been identified as an effective treatment of DME and have recently been approved by the US Food and Drug Administration (FDA) (9–11). We thus conducted this study to investigate anatomic and functional improvements of DEX implant treatment in a group of patients with DME refractory to previous ranibizumab injections.

MATERIALS AND METHODS

This retrospective, non-comparative, consecutive case series study was approved by the Institutional Ethics Committee and conducted in compliance with the tenets of the Declaration of Helsinki. We retrospectively analyzed the eyes of patients with DME refractory to intravitreal ranibizumab treatment, were

Abbreviations: DEX, dexamethasone; DME, diabetic macular edema; BCVA, best-corrected visual acuity; CRT, central retinal thickness; IOP, intraocular pressure; VEGF, vascular endothelial growth factor; BRB, blood-retinal barrier; FDA, Food and Drug Administration; HbA1c, glycated hemoglobin; ETDRS, Early Treatment Diabetic Retinopathy Study; GLMM, generalized linear mixed model.

treated with DEX implant between August 2013 and October 2017. Informed oral and written consent was obtained from all patients. Before March 2020, Taiwan National Health Insurance scheme only reimbursed 3 initial plus 5 additional injections of ranibizumab for eligible patients with DME. No switch to DEX was allowed. Therefore, patients had to continue 3 to 8 ranibizumab injections unless they decide to pay for DEX out of pocket.

The inclusion criteria were as follows: (1) a diagnosis of DME (the presentation of choroidal neovascularization with macular edema, confirmed by fluorescein angiography and optical coherence tomography [OCT]); (2) a history of treatment with at least 3 monthly intravitreal ranibizumab injections, followed by increasing or persistent sub-retinal fluid or retinal edema on OCT; and (3) a CRT >250 μm. The criteria for treatment with DEX implant were the same as the retreatment criteria for ranibizumab regarding the presence of intraretinal or subretinal fluid.

We recorded general patient data including age, sex, laterality, medical history, glycated hemoglobin (HbA1c), best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), and results of external ocular and slit-lamp examinations. Each patient underwent a thorough bilateral fundus examination by indirect ophthalmoscopy, fundus photography, fluorescein angiography, and spectral-domain OCT (Cirrus HD-OCT; Carl Zeiss Meditec, Inc., Dublin, CA) scans. Over the course of the treatment, patients received between one and three injections of DEX implant 0.7 mg (Ozurdex, Allergan, Inc, Irvine, CA). Before each DEX implantation, the topical antibiotic levofloxacin (Cravit, Santen Pharmaceutical Co., Osaka, Japan) was applied. Topical and subconjunctival anesthesia was achieved by 0.5% proparacaine hydrochloride (Alcaine, Alcon Pharmaceuticals, Puurs, Belgium) before surgery. Each eye was prepared in a sterile manner using 5% povidone/iodine. The DEX implant was inserted intravitreally via a pars plana puncture (3.5 mm away from the limbus). Application of levofloxacin eyedrops was prescribed four times a day for 1 week after the operation. Initial management with ranibizumab and the number of subsequent treatments with DEX implant were collected. All of the patients were scheduled for monthly follow-ups.

The main outcome measures included the mean change in CRT from baseline as measured by spectral-domain OCT and mean change in BCVA (approximate Early Treatment Diabetic Retinopathy Study [ETDRS] letter scores) from baseline during monthly follow-ups. Therefore, the outcome of DEX implant after ranibizumab was evaluated by analyzing changes in retinal anatomy and vision, with reference to patient characteristics and fundus findings. Safety was evaluated by recording complications and other adverse events during the follow-up period.

For statistical analyses, SAS 9.4 was used in this study. For comparison of cross-section data, one-way ANOVA was used for continuous data and Fisher's exact test was used for categorical data. For comparison of serial data, the principle of a generalized linear mixed model (GLMM) was applied using the GLIMMIX procedure in SAS. Generalized linear mixed model is actually a method with the same concept as repeated measured ANOVA for

serial data comparison but is more flexible and tolerant of data completeness. Shapiro-Wilk test and Kolmogorov-Smirnov tests were both used for normality test with SAS procedure univariate.

RESULTS

Study Population and Treatments

A total of 29 eyes of 26 patients with DME were included in this study. The study group comprised of 14 men and 12 women, and the mean age was 62.0 ± 9.1 (range 46–84) years. The mean baseline HbA1c was 7.5 ± 1.3 %. Before any treatment (baseline), the mean CRT was 384.4 ± 114.4 (range 248–727) µm (**Table 1**). After ranibizumab treatment, patients were followed up for an average of 12.4 ± 7.4 months. Prior to receiving DEX implant treatment, all patients had been treated with an average of 8.1 ± 4.4 (range 3–18) injections of intravitreal ranibizumab. The time between the last ranibizumab injection and the first DEX injection was a month. Each eye received an average of 1.3 ± 0.6 DEX implant (range 1–3) injections. Of the 29 study eyes, 23 eyes received only one DEX implant, four eyes received two DEX implants and two eyes received three DEX implants. The mean interval between DEX implant injections in the six eyes that received more than one injection was 5.93 ± 2.68 months (range $3.1 \sim 10.2$ months). The follow-up period before DEX was 12.39 ± 7.44 months, the follow-up period after DEX was 7.43 ± 4.60 months, and the entire follow-up period was 19.82 ± 8.96 months.

Anatomic Changes

Distribution of CRT thickness before DEX implant treatment were as follows: 16 eyes between 350 and 250 µm, 8 eyes

TABLE 1 | Baseline characteristics of the patients.

Baseline characteristics	Mean ± SD or (%)
Age (years)	62.0 ± 9.1
Gender ($n = 26$)	
Female	12 (46.2%)
Male	14 (53.8%)
Eyes ($n = 29$)	
OD	16 (55.2%)
OS	13 (44.8%)
Baseline BCVA (letter score)	44.9 ± 30.2
Baseline CRT (µm)	384.4 ± 114.4
Baseline IOP (mmHg)	14.9 ± 3.1
Lens status	
Phakic	20 (69%)
Pseudophakic	9 (31%)
Follow-up (months)	
Total	19.8 ± 9.0
Before ozurdex (anti-VEGF use)	12.4 ± 7.4
After ozurdex	7.4 ± 4.6

BCVA, best-corrected visual acuity; CRT, central retina thickness; IOP, intraocular pressure; VEGF, vascular endothelial growth factor.

between 450 and 350 µm, 3 eyes between 550 and 450 µm, 1 eye between 650 and 550 µm, and 1 eye >650 µm. All eyes showed anatomic improvement after switching to intravitreal DEX implant treatment, with significant postoperative changes in CRT as measured by OCT. After DEX implant treatment, the mean final CRT (323.9 ± 77.7, range 201–488 µm) was significantly lower than the baseline value (384.5 ± 114.4, range 248–727 µm) ($p = 0.0249$), and also significantly lower than the mean CRT at 1 month after the last injection of ranibizumab (375.5 ± 111.0, range 261–757 µm) ($p = 0.0265$; **Figure 1A**). The mean best CRT (the lowest CRT value recorded during follow-up)after ranibizumab treatment (302.1 ± 73.5, range 195–568 µm) was significantly lower than the baseline value ($p = 0.0004$), and it was maintained if not further improved after DEX implants (286.1 ± 56.3, range 172–414 µm) ($p < 0.0001$ compared to baseline; **Figure 1B**).

Changes in Best-Corrected Visual Acuity

After DEX implant treatment, the mean final BCVA (51.4 ± 21.3 letters) did not significantly improve as compared to baseline (44.9 ± 30.2 letters) ($p = 0.1149$; **Figure 2A**). However, the mean maximal BCVA (the highest letter score recorded during follow-up) after DEX implant (61.2 ± 17.4 letters) was significantly higher than baseline ($p = 0.0022$; **Figure 2B**).

Predictors of Therapeutic Response

Several baseline patient parameters were analyzed to explore the correlation with the treatment responses (**Table 2**). Thicker baseline CRT (**Figure 3**), lower HbA1c, and worse BCVA (**Figure 4**) had better responses to the treatment. Multivariate logistic regression and general linear model analyses confirmed the same results that thicker baseline CRT and worse baseline BCVA had better responses to the treatment ($p < 0.0001$).

Safety Outcomes

The mean final IOP (15.3 ± 3.2 mmHg) was not significantly higher than the baseline value (14.9 ± 3.1 mmHg, $p = 0.5643$), and not significantly higher than the IOP at 1 month after the last injection of ranibizumab (15.3 ± 3.3, $p = 0.9985$). The mean maximal IOP (the highest IOP recorded during follow-up) was 20.1 ± 4.7 mmHg, which was significantly higher than the baseline (14.9 ± 3.1 mmHg, $p < 0.0001$), but not significantly higher than the IOP at 1 month after the last ranibizumab injection (20.0 ± 4.5, mmHg, $p = 0.8480$). During the study, seven patients experienced IOP increases >22 mmHg after DEX implant, but all these patients had IOP returned to ≤22 mmHg after being managed with topical IOP-lowering medications.

All patients tolerated the treatment well, and none experienced serious ocular (e.g., endophthalmitis, non-infectious endophthalmitis, vitreous hemorrhage, retinal tear, retinal detachment, or sustained IOP elevations) or systemic adverse events during the follow-up period.

DISCUSSION

This retrospective case series, carried out in a tertiary medical center in central Taiwan, studied the therapeutic effects of DEX

FIGURE 1 | (A) Mean baseline and final CRT after the respective treatments. The mean final CRT after DEX implant treatment was significantly lower than the CRT (p = 0.0249) at baseline and 1 month after the last ranibizumab injection (p = 0.0265). **(B)** Mean best CRT (the lowest CRT value recorded during follow-up) at baseline and after the respective treatments. The mean best CRT after DEX implant treatment was significantly lower than the CRT (p < 0.0001) before treatment. *p < 0.05; **p < 0.001 compared to before-treatment data (Generalized linear mixed model).

implant treatment on DME in eyes that had been unsuccessfully treated with intravitreal ranibizumab. In this study, DEX implants were effective in the anatomical improvement. Patients were assessed at monthly intervals postoperatively, and anatomic improvements as gauged by CRT were sustained throughout the entire course of follow-up. Even though improvements in CRT did not correlate with significantly improved BCVA, neither did BCVA decrease over the course of treatment and follow-up. DEX implants were well-tolerated, with only a few cases of increased IOP that were manageable with antihypertensive eyedrops.

Currently, there is no optimal treatment regimen for DEX implant therapy for DME (12). In the MEAD study, the protocol allows as-needed (*pro re nata*, PRN) retreatment with DEX implant with a frequency of no more than once every 6 months (13). As the out-of-pocket expense for our patients was about 40,000 NTD (1,370 USD) for each DEX implant during the study, we treated most eyes with one dose of DEX implant, followed by PRN injections when macular edema reoccurred. During the mean follow-up of 7.4 ± 4.6 months, almost 80% of the patients

received only one DEX implant, and only two eyes received three injections.

The various available treatments for DME include anti-VEGFs, laser, surgery, and corticosteroids, with each targeting different pathogenic mechanisms of the disease (4). Our study suggests two main explanations for the observed benefit of DEX implant after refractory ranibizumab treatment: the pharmacologic and pharmacokinetic properties of the DEX implant and the possible tachyphylaxis or tolerance to ranibizumab. First, inflammation plays a prominent role in the pathogenesis of DME. Many features of inflammation, such as the leukocyte recruitment and adhesion to vascular endothelium (leukostasis), increased blood flow and vascular permeability, tissue (macular) edema, neovascularization, and upregulation of inflammatory mediators, have been described in both human and animal models of diabetic retinopathy (12, 14–18). Intravitreally administered corticosteroids act to ameliorate DME in multiple ways. As established anti-inflammatory agents, they reduce the production of pro-inflammatory factors, limit

FIGURE 2 | (A) Mean BCVA at baseline and after the respective treatments. There was no significant improvement in BCVA 1 month after the last ranibizumab and after DEX implant treatment. **(B)** Mean maximal BCVA (the highest letter score recorded during follow-up) at baseline and after respective treatments. The mean maximal BCVA after DEX implant treatment was significantly higher than baseline BCVA ($p = 0.0022$). *$p < 0.05$ compared to before-treatment data (Generalized linear mixed model).

**TABLE 2 |** Clinical parameters of patients with different therapeutic responses.

	ΔCRT ≤ −50 n = 12 (41.38%)	ΔCRT > −50 n = 17 (58.62%)	p	ΔBCVA ≥ 15 n = 8 (27.59%)	ΔBCVA< 15 n = 21 (72.41%)	p
Initial CRT 2	477.17 ± 106.90	319.00 ± 63.61	<0.0001*	420.38 ± 134.10	370.76 ± 106.37	0.305
Initial HbA1c	6.65 ± 0.59	7.99 ± 1.61	0.018*	7.12 ± 1.41	7.60 ± 1.50	0.487
Age	61.17 ± 10.25	61.94 ± 7.82	0.819	57.25 ± 6.09	63.29 ± 9.13	0.097
Gender						
Female	7 (58.33%)	6 (35.29%)	0.274	6 (75.00%)	7 (33.33%)	0.092
Male	5(41.67%)	11 (64.71%)		2 (25.00%)	14 (66.67%)	
Initial BCVA (Letters)	37.42 ± 27.27	50.24 ± 31.89	0.269	18.63 ± 40.19	54.95 ± 18.24	0.002*
Initial IOP	14.67 ± 2.93	15.12 ± 3.33	0.709	14.13 ± 3.00	15.24 ± 3.19	0.402
Anti-VEGF injection times	9.00 ± 4.43	7.53 ± 4.32	0.379	9.88 ± 3.80	7.48 ± 4.45	0.189
Lens status						
Phakic	9 (75.00%)	11 (64.71%)	0.694	7 (87.50%)	13 (61.90%)	
Pseudophakic	3 (25.00%)	6 (35.29%)		1 (12.50%)	8 (38.10%)	

*$p < 0.05$; BCVA, best-corrected visual acuity; CRT, central retina thickness; HbA1c, glycated hemoglobin; IOP, intraocular pressure; VEGF, vascular endothelial growth factor.

vascular permeability, and inhibit the expression of VEGFs (19). The DEX implant, a sustained-release drug delivery system for the potent corticosteroid dexamethasone, was developed to reduce the need for frequent intraocular injections due to the short half-life of intravitreally injected dexamethasone (<4 h) (20). The implant releases DEX into the vitreous for up to 6 months (21). In a previous study, Lazic et al. demonstrated the therapeutic efficacy of DEX implant for DME resistant to

**FIGURE 3 |** Correlation between changes in CRT and baseline CRT.

the anti-VEGF bevacizumab (22). The use of bevacizumab for DME is off-label, and therefore we examined patients who were initially treated with ranibizumab, which is FDA-approved for DME. Second, the patients' tachyphylaxis/tolerance to the previously administered ranibizumab might be another possible mechanism for the observed therapeutic effect after switching to intravitreal DEX implant. Even though there is a difference between tachyphylaxis and tolerance, both terms have long been presented as phenomena of reduced drug efficacy and are used synonymously in the literature (23). Tachyphylaxis/tolerance in chronic treatment with bevacizumab and ranibizumab was first described in 2007 for age-related macular degeneration (24, 25). Tachyphylaxis/tolerance to ranibizumab might be a result of the neutralization of ranibizumab by the formation of circulating antibodies, the desensitization of the target tissue to the drug, or the reactivation of DME driven by another pathway (26, 27). These effects might be circumvented with the use of pharmaceuticals aiming at other DME-associated pathways.

In our study, DEX implant treatment showed a generally favorable safety profile. Historically, adverse events most

commonly associated with corticosteroid therapy include cataracts and steroid-induced glaucoma. Although none of our patients received a cataract surgery after DEX implants, the mean follow-up period was about 7 months, which may not be sufficient for the worsening of cataracts. Some patients in this study experienced transient increase in IOP that were successfully managed with topical medication. There was no case of serious ocular or systemic adverse events such as endophthalmitis, non-infectious endophthalmitis, vitreous hemorrhage, retinal tear, retinal detachment, or sustained IOP elevations.

We found three clinical factors that correlated with the treatment responses. Patients with lower baseline HbA1c had better anatomic improvement after treatment. The importance of glycemic control in the management of diabetic retinopathy was emphasized by previous studies (28, 29). The other two baseline predictive factors were thicker CRT and worse BCVA. Both factors correlated with better responses to DEX treatment in their respective aspects. Campos et al. also found that lower baseline BCVA predicted a higher visual acuity gain (30). It may be

FIGURE 4 | Correlation between changes in BCVA and baseline BCVA.

suggestive of a "ceiling effect" that cannot be ruled out completely in this prediction model; that is, smaller improvements are required to achieve good vision in patients with better starting vision, while those with lower BCVA at baseline have greater capacity to achieved better vision outcome. Another limit of visual acuity improvement was the uncertain optimal timing for DEX switching in patients with DME non-responder to intravitreal ranibizumab. If we can determine patients with DME who are more response to DEX implants, early switch to DEX implant may be performed, which may additional improve their final visual acuity. Limitations of this study include the small sample size and short-term follow-up, the uncontrolled retrospective design of the study, the non-standard treatment protocols, and a lack of consistent performance of fluorescein angiography prior to switching to DEX implant treatment. Nevertheless, this study showed that intravitreal DEX implant treatment was effective immediately after switch and safe in cases of refractory DME resistant to ranibizumab. Switching to DEX implant can be considered in eyes with DME that do not respond to anti-VEGF treatments. Furthermore, higher baseline CRT and

worse BCVA were found to be the predictive factors for better therapeutic responses. However, further studies are necessary to determine the optimal timing for DEX switching in patients with DME non-responder to intravitreal ranibizumab and to shed light on the long-term outcomes of this treatment modality.

CONCLUSION

This study demonstrated the feasibility of switching to intravitreal DEX implant in cases of DME that are refractory to intravitreal ranibizumab treatment. Conversion to DEX implant treatment resulted in a significant improvement in CRT. Although BCVA decreased a little after DEX treatment compared with BCVA after anti-VEGF injections, there was no statistical significance. Nevertheless, higher baseline CRT and worse BCVA can predict better therapeutic responses. Further larger-scale or multicenter studies would be conducted to explore different DEX treatment strategies for DME, such as first-line or early switch therapy, for better BCVA improvement.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by China medical university and hospital research ethics committee-CMUH109-REC3-158. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. Written informed consent for publication of his clinical details and clinical images was obtained from the patient.

AUTHOR CONTRIBUTIONS

N-YH, C-JL, H-SC, C-HC, C-TL, J-ML, W-LC, P-TT, and Y-YT were responsible for substantial contributions to the conception or design of the work, and acquisition of data. C-JL, H-SC, and C-HC were responsible for interpretation of results. N-YH, C-JL, and HB participated in the design and was a major contributor in writing the manuscript. N-YH, C-JL, HB, W-LC, and W-CW were responsible for final approval of the version to be published. All authors reviewed and approved the final manuscript.

REFERENCES

1. International Diabetes Federation. *IDF Diabetes Atlas. 8th edn.* Brussels: International Diabetes Federation (2017).
2. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T et al. Meta-Analysis for eye disease (META-EYE) study group. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care.* (2012) 35:556–64. doi: 10.2337/dc11-1909
3. Cebeci Z, Kir N. Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant. *Diabetes Metab Syndr Obes.* (2015) 8:555–66. doi: 10.2147/DMSO.S73540
4. Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. *Ophthalmology.* (2015) 122:1375–94. doi: 10.1016/j.ophtha.2015.03.024
5. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Diabetic retinopathy clinical research network. aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. *Ophthalmology.* (2016) 123:1351–9. doi: 10.1016/j.ophtha.2016.02.022
6. Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. *Ophthalmology.* (2014) 121:1045–53. doi: 10.1016/j.ophtha.2013.11.041
7. Totan Y, Guler E. Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment. *Curr Eye Res.* (2016) 41:107–13. doi: 10.3109/02713683.2014.1002048
8. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. *Retina.* (2008) 28:1053–60. doi: 10.1097/IAE.0b013e318176de48
9. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. *Arch Ophthalmol.* (2010) 128:289–96. doi: 10.1001/archophthalmol.2010.21
10. Mehta H, Gillies M, Fraser-Bell S. Perspective on the role of ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema. *Ther Adv Chronic Dis.* (2015) 6:234–45. doi: 10.1177/2040622315590319
11. Pareja-Ríos A, Ruiz-de la Fuente-Rodríguez P, Bonaque-González S, López-Gálvez M, Lozano-López V, Romero-Aroca P. Intravitreal dexamethasone implants for diabetic macular edema. *Int J Ophthalmol.* (2018) 11:77–82. doi: 10.18240/ijo.2018.01.14
12. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. *J Diabetes Complications.* (2001) 15:257–9. doi: 10.1016/S1056-8727(01)00155-6

13. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. *Ophthalmology.* (2014) 121:1905–14. doi: 10.1016/j.ophtha.2014.04.024
14. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. *Diabetes.* (2006) 55:2401–11. doi: 10.2337/db05-1635
15. Meleth AD, Agrón E, Chan CC, Reed GF, Arora K, Byrnes G, et al. Serum inflammatory markers in diabetic retinopathy. *Invest Ophthalmol Vis Sci.* (2005) 46:4295–301. doi: 10.1167/iovs.04-1057
16. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. *FASEB J.* (2004) 18:1450–2. doi: 10.1096/fj.03-1476fje
17. Semeraro F, Cancarini A, dell'Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic retinopathy: vascular and inflammatory disease. *J Diabetes Res.* (2015) 2015:582060. doi: 10.1155/2015/582060
18. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. *Semin Immunopathol.* (2008) 30:65–84. doi: 10.1007/s00281-008-0111-x
19. Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. *Biol Pharm Bull.* (2008) 31:1541–46. doi: 10.1248/bpb.31.1541
20. Calvo P, Ferreras A, Al Adel F, Dangboon W, Brent MH. Effect of an intravitreal dexamethasone implant on diabetic macular edema after cataract surgery. *Retina.* (2018) 38:490–6. doi: 10.1097/IAE.0000000000001552
21. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. *Invest Ophthalmol Vis Sci.* (2011) 52:80–6. doi: 10.1167/iovs.10-5285
22. Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N, et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. *Retina.* (2014) 34:719–24. doi: 10.1097/IAE.0b013e3182a48958
23. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? *Br J Ophthalmol.* (2012) 96:1–2. doi: 10.1136/bjophthalmol-2011-301236
24. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal antivascular endothelial growth factor pharmacotherapy in age-related macular degeneration? *Ophthalmology.* (2008) 115:2199–205. doi: 10.1016/j.ophtha.2008.07.007
25. Keane PA, Liakopoulos S, Ongchin SC, Heussen FM, Msutta S, Chang KT, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. *Invest Ophthalmol Vis Sci.* (2008) 49:3115–20. doi: 10.1167/iovs.08-1689

26. Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. *Br J Ophthalmol.* (2012) 96:14–20. doi: 10.1136/bjo.2011.204685

27. Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. *Br J Ophthalmol.* (2012) 96:21–3. doi: 10.1136/bjo.2011.203893

28. Matsuda S, Tam T, Singh RP, Kaiser PK, Petkovsek D, Carneiro G, et al. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. *J Diabetes Complications.* (2014) 28:166–70. doi: 10.1016/j.jdiacomp.2013.11.009

29. Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, et al. Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti–vascular endothelial growth factor therapy: an exploratory analysis of the protocol t randomized clinical trial. *JAMA Ophthalmol.* (2019) 137:382–9. doi: 10.1001/jamaophthalmol.2018.6786

30. Campos A, Campos EJ, do Carmo A, Caramelo F, Martins J, Sousa JP, et al. Evaluation of markers of outcome in real-world treatment of diabetic macular edema. *Eye Vis.* (2018) 5:27. doi: 10.1186/s40662-018-0119-9